The observational, noninterventional study was part of an emicizumab clinical development program in which a daily bleed and medication questionnaire developed by the sponsor on a handheld device was used to prospectively collect data on treatment with factor VIII or bypassing agents in adult and adolescent people with hemophilia A, with and without inhibitors to FVIII.
Despite efforts to standardize the definition of “new bleeds” in hemophilia A clinical trials, cross-study comparisons of these end points remain compromised by different bleed definitions, analysis methodology, and data-collection approaches. A study presented at the 60th Annual Meeting & Exposition of the American Society of Hematology (ASH), in San Diego, California, explored the daily bleed and medication diaries of patients with hemophilia A to examine the differences between treated and untreated bleeds.
Such patient diaries may provide a more detailed picture of the effectiveness of therapies and can help investigators understand why some bleeds are treated, and some are not, as well as their causes. Dr. Callaghan and colleagues presented their findings at the 60th ASH Annual Meeting & Exposition in San Diego, CA, on December 2, 2018.
The observational, noninterventional study (NIS) was part of an emicizumab (Hemlibra; Genentech/Roche) clinical development program in which a daily bleed and medication questionnaire (BMQ) developed by the sponsor on a handheld device was used to prospectively collect data on treatment with factor VIII (FVIII) or bypassing agents (BPA) in adult and adolescent people with hemophilia A (PwHA), with and without inhibitors to FVIII. The BMQ collected real-world data about all bleeds, including location, whether they were treated or untreated, medications used, reasons for medication use, and whether FVIII or BPAs were used. The study allowed researchers to examine the differences between treated and untreated bleeds, as well as any differences in their incidence between the inhibitor and non-inhibitor populations. Eligible participants from the NIS could subsequently enroll in a phase 3 trial of emicizumab.
The study recruited male hemophilia A patients aged 12 years and older, as well as children less than 12 years of age. There were 103 patients in the inhibitor group and 94 in the noninhibitor group; in the pediatric group there were 24 patients. The median efficacy period was 26.0 and 29.8 weeks, respectively. Median efficacy in the pediatric group was 23.4 weeks.
The study is the first to report large numbers of untreated bleeds in PwHA, particularly those with inhibitors, in whom approximately 40% of all bleeds were untreated. The BMQ allowed participants to capture bleeds and bleed treatments independently and enabled details about untreated and treated bleeds—as opposed to what has been captured in most clinical studies to date: only bleeds where a treatment was administered, according to the researchers. The reason for the large difference in the proportion of untreated bleeds in the inhibitor population versus the noninhibitor population is unknown and warrants further investigation, but it may be at least partially due to higher confidence in the efficacy of FVIII, less treatment burden, and better drug availability compared with BPAs. “This may therefore influence the patient’s decision on whether or not to treat,” the authors state.
The study shows that further efforts to harmonize bleed definitions, analyses of methodology, and data collection in hemophilia A clinical trials are needed in order to provide transparency on treated and untreated bleeds, as the latter might have been underreported, the investigators conclude. Capturing untreated bleeds in future trials could provide useful insights to physicians and researchers.
Reference
Callaghan MU, Asikanius E, Lehle M, et al. Untreated bleeds may be historically underreported and more prevalent in people with hemophilia A with inhibitors: an examination of bleed data from a prospective, non-interventional study. In: Proceedings from the 60 American Society of Hematology Annual Meeting & Exposition, San Diego, CA, December 2, 2018. Abstract 383.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen